• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cross Country Healthcare Announces First Quarter 2025 Financial Results

    5/7/25 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary
    Get the next $CCRN alert in real time by email

    Cross Country Healthcare, Inc. (the Company) (NASDAQ:CCRN) today announced financial results for its first quarter ended March 31, 2025.

    SELECTED FINANCIAL INFORMATION:

     

     

     

    Variance

    Variance

     

     

     

    Q1 2025 vs

    Q1 2025 vs

    Dollars are in thousands, except per share amounts

    Q1 2025

    Q1 2024

    Q4 2024

    Revenue

    $

    293,408

     

     

     

    (23

    )

    %

     

    (5

    )

    %

    Gross profit margin*

     

    20.0

     

    %

     

    (40

    )

    bps

     

    —

     

    bps

    Net loss attributable to common stockholders

    $

    (490

    )

     

     

    (118

    )

    %

     

    87

     

    %

    Diluted EPS

    $

    (0.02

    )

     

    $

    (0.10

    )

     

    $

    0.10

     

     

    Adjusted EBITDA*

    $

    8,619

     

     

     

    (44

    )

    %

     

    (7

    )

    %

    Adjusted EBITDA margin*

     

    2.9

     

    %

     

    (110

    )

    bps

     

    (10

    )

    bps

    Adjusted EPS*

    $

    0.06

     

     

    $

    (0.13

    )

     

    $

    0.02

     

     

    Cash flows provided by operations

    $

    5,681

     

     

     

    (5

    )

    %

     

    (77

    )

    %

     

    * Represents amounts that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP) and are referred to as non-GAAP measures. Please refer to the accompanying discussion below of how these non-GAAP financial measures are calculated and used under "Non-GAAP Financial Measures" and the tables reconciling these measures to the closest GAAP measure.

    First Quarter Business Highlights

    • Homecare Staffing experienced double-digit sequential and year-over-year revenue growth
    • Physician Staffing experienced year-over-year revenue growth
    • Cross Country Education experienced double-digit sequential revenue growth
    • Continued strong balance sheet with $81 million of cash on hand and no debt as of March 31, 2025

    "Our first quarter results reflect solid execution with both Homecare and Physician Staffing business reporting solid year over year growth," said John A. Martins, President and Chief Executive Officer of Cross Country Healthcare. He continued, "As the market for core nurse and allied continues to stabilize, we remain focused on driving productivity across our business, leveraging our investments in AI automation as well as our cost-effective center of excellence in India to fuel efficiency and improved profitability. Looking ahead, we continue working with Aya Healthcare and the Federal Trade Commission towards the successful consummation of the merger transaction in the second half of this year."

    Regarding the Company's pending acquisition by Aya Healthcare, Martins further commented, "We recently learned of the passing of Alan Braynin, founder, former CEO & President of Aya Healthcare, and our hearts go out to his family, friends and to the thousands of Aya employees. Alan was a pioneer and transformational force in the healthcare staffing industry whose presence will be missed by many."

    First quarter consolidated revenue was $293.4 million, a decrease of 23% year-over-year and 5% sequentially. Consolidated gross profit margin was 20.0%, down 40 basis points year-over-year and flat sequentially. Net loss attributable to common stockholders was $0.5 million, as compared to net income of $2.7 million in the prior year and a net loss of $3.8 million in the prior quarter. Diluted earnings per share (EPS) was a net loss of $0.02, as compared to net income of $0.08 in the prior year and a net loss of $0.12 in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was $8.6 million, or 2.9% of revenue, as compared with $15.3 million, or 4.0% of revenue, in the prior year, and $9.3 million, or 3.0% of revenue, in the prior quarter. Adjusted EPS was $0.06, as compared to $0.19 in the prior year and $0.04 in the prior quarter.

    Quarterly Business Segment Highlights

    Nurse and Allied Staffing

    Revenue was $242.3 million, a decrease of 27% year-over-year and 6% sequentially. Contribution income was $17.2 million, as compared to $27.2 million in the prior year and $20.3 million in the prior quarter. Average field contract personnel on a full-time equivalent (FTE) basis was 7,411, as compared with 9,124 in the prior year and 7,621 in the prior quarter. Revenue per FTE per day was $360, as compared to $397 in the prior year and $363 in the prior quarter.

    Physician Staffing

    Revenue was $51.1 million, an increase of 9% year-over-year and a decrease of 4% sequentially. Contribution income was $4.0 million, as compared to $3.1 million in the prior year and $3.5 million in the prior quarter. Total days filled were 22,692, as compared with 23,785 in the prior year and 25,427 in the prior quarter. Revenue per day filled was $2,253, as compared with $1,976 in the prior year and $2,085 in the prior quarter.

    Cash Flow and Balance Sheet Highlights

    Net cash provided by operating activities for the three months ended March 31, 2025 was $5.7 million, as compared to $6.0 million for the three months ended March 31, 2024 and $24.2 million for the three months ended December 31, 2024. We experienced a 15-day year-over-year improvement in days' sales outstanding.

    During the first quarter of 2025, the Company did not repurchase any shares of its common stock. As of March 31, 2025, the Company had 32.5 million unrestricted shares outstanding and $40.5 million remaining for share repurchase.

    As of March 31, 2025, the Company had $80.7 million in cash and cash equivalents with no debt outstanding. There were no borrowings drawn under its revolving senior secured asset-based credit facility (ABL). As of March 31, 2025, borrowing base availability under the ABL was $148.4 million, with $133.5 million of availability net of $14.9 million of letters of credit.

    CONFERENCE CALL

    As previously disclosed, on December 3, 2024, the Company entered into a merger agreement with Aya Healthcare, Inc. and certain of its subsidiaries (Aya Merger, and such agreement, the Merger Agreement). In light of the pending transaction, the Company will not host an earnings conference call to review first quarter 2025 financial results, nor will it provide forward-looking guidance. This press release is also posted on the Company's website at ir.crosscountry.com.

    ABOUT CROSS COUNTRY HEALTHCARE

    Cross Country Healthcare, Inc. is a market-leading, tech-enabled workforce solutions and advisory firm with 39 years of industry experience and insight. We help clients tackle complex labor-related challenges and achieve high-quality outcomes, while reducing complexity and improving visibility through data-driven insights.

    Copies of this and other press releases, information about the Company, as well as information about the Aya Merger, can be accessed online at ir.crosscountry.com. Stockholders and prospective investors can also register to automatically receive the Company's press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail.

    NON-GAAP FINANCIAL MEASURES

    This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, adjusted EBITDA margin, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes such non-GAAP financial measures are useful to investors when evaluating the Company's performance, as such non-GAAP financial measures exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

    FORWARD-LOOKING STATEMENTS

    This press release contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact, including statements relating to our future results (including business trends); statements regarding the proposed Aya Merger; the expected timing and closing of the proposed Aya Merger; the Company's ability to consummate the proposed Aya Merger; the expected benefits of the proposed Aya Merger and other considerations taken into account by the Board in approving the proposed Aya Merger; the amounts to be received by stockholders in connection with the proposed Aya Merger; and expectations for the Company prior to and following the closing of the proposed Aya Merger, may be deemed to be forward-looking statements. All such forward-looking statements are intended to provide management's current expectations for the future of the Company based on current expectations and assumptions relating to the Company's business, the economy and other future conditions. Forward-looking statements generally can be identified through the use of words such as "believes," "anticipates," "may," "should," "will," "plans," "projects," "expects," "expectations," "estimates," "forecasts," "predicts," "targets," "prospects," "strategy," "signs," and other words of similar meaning in connection with the discussion of future performance, plans, actions or events. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict. Such risks and uncertainties include, among others: (i) the timing to consummate the proposed Aya Merger, (ii) the risk that a condition of closing of the proposed Aya Merger may not be satisfied or that the closing of the proposed Aya Merger might otherwise not occur, (iii) the risk that a regulatory approval that may be required for the proposed Aya Merger is not obtained or is obtained subject to conditions that are not anticipated, (iv) the diversion of management time on transaction-related issues, (v) risks related to disruption of management time from ongoing business operations due to the proposed Aya Merger, (vi) the risk that any announcements relating to the proposed Aya Merger could have adverse effects on the market price of the common stock of the Company, (vii) the risk that the proposed Aya Merger and its announcement could have an adverse effect on the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with its suppliers and customers, (viii) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement, including in circumstances requiring the Company to pay a termination fee, (ix) the risk that competing offers will be made, (x) unexpected costs, charges or expenses resulting from the Aya Merger, (xi) potential litigation relating to the Aya Merger that could be instituted against the parties to the Merger Agreement or their respective directors, managers or officers, including the effects of any outcomes related thereto, (xii) worldwide economic or political changes that affect the markets that the Company's businesses serve which could have an effect on demand for the Company's services and impact the Company's profitability, (xiii) effects from global pandemics, epidemics or other public health crises, (xiv) changes in marketplace conditions, such as alternative modes of healthcare delivery, reimbursement and customer needs, and (xv) disruptions in the global credit and financial markets, including diminished liquidity and credit availability, changes in international trade agreements, including tariffs and trade restrictions, cyber-security vulnerabilities, foreign currency volatility, swings in consumer confidence and spending, costs of providing services, retention of key employees, and outcomes of legal proceedings, claims and investigations. Accordingly, actual results may differ materially from those contemplated by these forward-looking statements. Investors, therefore, are cautioned against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the SEC, including the risks and uncertainties identified in Part I, Item 1A - Risk Factors of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as amended by Amendment No. 1 on Form 10-K/A, and in the Company's other filings with the SEC. The list of factors is not intended to be exhaustive.

    These forward-looking statements speak only as of the date of this press release, and the Company does not assume any obligation to update or revise any forward-looking statement made in this press release or that may from time to time be made by or on behalf of the Company.

    Cross Country Healthcare, Inc.

    Consolidated Statements of Operations

    (Unaudited, amounts in thousands, except per share data)

     

     

     

     

     

     

     

    Three Months Ended

     

    March 31,

     

    March 31,

     

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2024

     

     

     

    Revenue from services

    $

    293,408

     

     

    $

    379,174

     

     

    $

    309,940

     

    Operating expenses:

     

     

     

     

     

    Direct operating expenses

     

    234,750

     

     

     

    301,877

     

     

     

    247,948

     

    Selling, general and administrative expenses

     

    52,486

     

     

     

    63,252

     

     

     

    55,573

     

    Credit loss expense (income)

     

    35

     

     

     

    1,290

     

     

     

    (228

    )

    Depreciation and amortization

     

    4,772

     

     

     

    4,642

     

     

     

    4,341

     

    Acquisition and integration-related costs

     

    2,041

     

     

     

    —

     

     

     

    4,216

     

    Restructuring costs

     

    301

     

     

     

    938

     

     

     

    281

     

    Legal and other losses (gains)

     

    —

     

     

     

    3,650

     

     

     

    (928

    )

    Impairment charges

     

    —

     

     

     

    604

     

     

     

    2,170

     

    Total operating expenses

     

    294,385

     

     

     

    376,253

     

     

     

    313,373

     

    (Loss) income from operations

     

    (977

    )

     

     

    2,921

     

     

     

    (3,433

    )

    Other expenses (income):

     

     

     

     

     

    Interest expense

     

    543

     

     

     

    462

     

     

     

    608

     

    Interest income

     

    (681

    )

     

     

    (173

    )

     

     

    (535

    )

    Other expense (income) , net

     

    60

     

     

     

    (1,057

    )

     

     

    408

     

    (Loss) income before income taxes

     

    (899

    )

     

     

    3,689

     

     

     

    (3,914

    )

    Income tax (benefit) expense

     

    (409

    )

     

     

    997

     

     

     

    (161

    )

    Net (loss) income attributable to common stockholders

    $

    (490

    )

     

    $

    2,692

     

     

    $

    (3,753

    )

     

     

     

     

     

     

    Net (loss) income per share attributable to common stockholders - Basic

    $

    (0.02

    )

     

    $

    0.08

     

     

    $

    (0.12

    )

     

     

     

     

     

     

    Net (loss) income per share attributable to common stockholders - Diluted

    $

    (0.02

    )

     

    $

    0.08

     

     

    $

    (0.12

    )

     

     

     

     

     

     

    Weighted average common shares outstanding:

     

     

     

     

     

    Basic

     

    32,282

     

     

     

    34,216

     

     

     

    32,338

     

    Diluted

     

    32,282

     

     

     

    34,597

     

     

     

    32,338

     

    Cross Country Healthcare, Inc.

    Reconciliation of Non-GAAP Financial Measures

    (Unaudited, amounts in thousands, except per share data)

     

     

    Three Months Ended

     

    March 31,

     

    March 31,

     

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2024

     

    Adjusted EBITDA:a

     

     

     

     

     

    Net (loss) income attributable to common stockholders

    $

    (490

    )

     

    $

    2,692

     

     

    $

    (3,753

    )

    Interest expense

     

    543

     

     

     

    462

     

     

     

    608

     

    Income tax (benefit) expense

     

    (409

    )

     

     

    997

     

     

     

    (161

    )

    Depreciation and amortization

     

    4,772

     

     

     

    4,642

     

     

     

    4,341

     

    Acquisition and integration-related costsb

     

    2,041

     

     

     

    —

     

     

     

    4,216

     

    Restructuring costsc

     

    301

     

     

     

    938

     

     

     

    281

     

    Legal, bankruptcy, and other losses (gains)d

     

    —

     

     

     

    3,650

     

     

     

    (928

    )

    Impairment chargese

     

    —

     

     

     

    604

     

     

     

    2,170

     

    Loss on disposal of fixed assets

     

    —

     

     

     

    —

     

     

     

    86

     

    Interest incomef

     

    (681

    )

     

     

    (173

    )

     

     

    (535

    )

    Other expense (income), net

     

    60

     

     

     

    (1,057

    )

     

     

    322

     

    Equity compensation

     

    1,318

     

     

     

    1,198

     

     

     

    1,698

     

    System conversion costsg

     

    1,164

     

     

     

    1,329

     

     

     

    926

     

    Adjusted EBITDAa

    $

    8,619

     

     

    $

    15,282

     

     

    $

    9,271

     

    Adjusted EBITDA margina

     

    2.9

    %

     

     

    4.0

    %

     

     

    3.0

    %

     

     

     

     

     

     

    Adjusted EPS:h

     

     

     

     

     

    Numerator:

     

     

     

     

     

    Net (loss) income attributable to common stockholders

    $

    (490

    )

     

    $

    2,692

     

     

    $

    (3,753

    )

    Non-GAAP adjustments - pretax:

     

     

     

     

     

    Acquisition and integration-related costsb

     

    2,041

     

     

     

    —

     

     

     

    4,216

     

    Restructuring costsc

     

    301

     

     

     

    938

     

     

     

    281

     

    Legal, bankruptcy, and other losses (gains)d

     

    —

     

     

     

    3,650

     

     

     

    (928

    )

    Impairment chargese

     

    —

     

     

     

    604

     

     

     

    2,170

     

    Other (income) expense, net

     

    —

     

     

     

    (1,115

    )

     

     

    311

     

    System conversion costsg

     

    1,164

     

     

     

    1,329

     

     

     

    926

     

    Tax impact of non-GAAP adjustments

     

    (919

    )

     

     

    (1,405

    )

     

     

    (1,843

    )

    Adjusted net income attributable to common stockholders - non-GAAP

    $

    2,097

     

     

    $

    6,693

     

     

    $

    1,380

     

     

     

     

     

     

     

    Denominator:

     

     

     

     

     

    Weighted average common shares - basic, GAAP

     

    32,282

     

     

     

    34,216

     

     

     

    32,338

     

    Dilutive impact of share-based payments

     

    281

     

     

     

    381

     

     

     

    68

     

    Adjusted weighted average common shares - diluted, non-GAAP

     

    32,563

     

     

     

    34,597

     

     

     

    32,406

     

     

     

     

     

     

     

    Reconciliation:

     

     

     

     

     

    Diluted EPS, GAAP

    $

    (0.02

    )

     

    $

    0.08

     

     

    $

    (0.12

    )

    Non-GAAP adjustments - pretax:

     

     

     

     

     

    Acquisition and integration-related costsb

     

    0.06

     

     

     

    —

     

     

     

    0.13

     

    Restructuring costsc

     

    0.01

     

     

     

    0.02

     

     

     

    0.01

     

    Legal, bankruptcy, and other losses (gains)d

     

    —

     

     

     

    0.10

     

     

     

    (0.03

    )

    Impairment chargese

     

    —

     

     

     

    0.02

     

     

     

    0.07

     

    Other (income) expense, net

     

    —

     

     

     

    (0.03

    )

     

     

    0.01

     

    System conversion costsg

     

    0.04

     

     

     

    0.04

     

     

     

    0.03

     

    Tax impact of non-GAAP adjustments

     

    (0.03

    )

     

     

    (0.04

    )

     

     

    (0.06

    )

    Adjusted EPS, non-GAAPh

    $

    0.06

     

     

    $

    0.19

     

     

    $

    0.04

    Cross Country Healthcare, Inc.

    Consolidated Balance Sheets

    (Unaudited, amounts in thousands)

     

     

    March 31,

     

     

    December 31,

     

     

    2025

     

     

     

     

    2024

     

     

     

     

     

     

    Assets

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

    $

    80,697

     

     

     

    $

    81,633

     

    Accounts receivable, net

     

    219,789

     

     

     

     

    223,238

     

    Income taxes receivable

     

    5,893

     

     

     

     

    10,389

     

    Prepaid expenses

     

    8,295

     

     

     

     

    7,848

     

    Insurance recovery receivable

     

    9,343

     

     

     

     

    9,255

     

    Other current assets

     

    1,182

     

     

     

     

    2,637

     

    Total current assets

     

    325,199

     

     

     

     

    335,000

     

    Property and equipment, net

     

    28,117

     

     

     

     

    28,850

     

    Operating lease right-of-use assets

     

    2,219

     

     

     

     

    2,468

     

    Goodwill

     

    135,060

     

     

     

     

    135,060

     

    Other intangible assets, net

     

    39,965

     

     

     

     

    42,186

     

    Deferred tax assets

     

    8,804

     

     

     

     

    8,104

     

    Insurance recovery receivable

     

    20,193

     

     

     

     

    20,928

     

    Cloud computing

     

    11,358

     

     

     

     

    10,846

     

    Other assets

     

    5,320

     

     

     

     

    5,809

     

    Total assets

    $

    576,235

     

     

     

    $

    589,251

     

     

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable and accrued expenses

    $

    56,325

     

     

     

    $

    64,946

     

    Accrued compensation and benefits

     

    50,056

     

     

     

     

    47,646

     

    Operating lease liabilities

     

    1,687

     

     

     

     

    2,089

     

    Earnout liability

     

    —

     

     

     

     

    4,411

     

    Other current liabilities

     

    980

     

     

     

     

    1,310

     

    Total current liabilities

     

    109,048

     

     

     

     

    120,402

     

    Operating lease liabilities

     

    1,623

     

     

     

     

    1,782

     

    Accrued claims

     

    33,982

     

     

     

     

    34,425

     

    Uncertain tax positions

     

    10,168

     

     

     

     

    10,117

     

    Other liabilities

     

    3,204

     

     

     

     

    3,566

     

    Total liabilities

     

    158,025

     

     

     

     

    170,292

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

    Common stock

     

    3

     

     

     

     

    3

     

    Additional paid-in capital

     

    202,074

     

     

     

     

    202,338

     

    Accumulated other comprehensive loss

     

    (1,436

    )

     

     

     

    (1,441

    )

    Retained earnings

     

    217,569

     

     

     

     

    218,059

     

    Total stockholders' equity

     

    418,210

     

     

     

     

    418,959

     

    Total liabilities and stockholders' equity

    $

    576,235

     

     

     

    $

    589,251

     

    Cross Country Healthcare, Inc.

    Segment Datai

    (Unaudited, amounts in thousands)

     

     

    Three Months Ended

     

    Year-over-Year

     

    Sequential

     

    March 31,

    % of

     

    March 31,

    % of

     

    December 31,

    % of

     

    % change

     

    % change

     

    2025

    Total

     

    2024

    Total

     

    2024

    Total

     

    Fav (Unfav)

     

    Fav (Unfav)

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue from services:

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    242,291

     

    83

    %

     

    $

    332,186

    88

    %

     

    $

    256,929

     

    83

    %

     

    (27

    )%

     

    (6

    )%

    Physician Staffing

     

    51,117

     

    17

    %

     

     

    46,988

    12

    %

     

     

    53,011

     

    17

    %

     

    9

    %

     

    (4

    )%

     

    $

    293,408

     

    100

    %

     

    $

    379,174

    100

    %

     

    $

    309,940

     

    100

    %

     

    (23

    )%

     

    (5

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Contribution income:j

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    17,244

     

     

     

    $

    27,183

     

     

    $

    20,347

     

     

     

    (37

    )%

     

    (15

    )%

    Physician Staffing

     

    4,029

     

     

     

     

    3,138

     

     

     

    3,549

     

     

     

    28

    %

     

    14

    %

     

     

    21,273

     

     

     

     

    30,321

     

     

     

    23,896

     

     

     

    (30

    )%

     

    (11

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Corporate overheadk

     

    15,136

     

     

     

     

    17,566

     

     

     

    17,249

     

     

     

    14

    %

     

    12

    %

    Depreciation and amortization

     

    4,772

     

     

     

     

    4,642

     

     

     

    4,341

     

     

     

    (3

    )%

     

    (10

    )%

    Restructuring costsc

     

    301

     

     

     

     

    938

     

     

     

    281

     

     

     

    68

    %

     

    (7

    )%

    Legal and other losses (gains)l

     

    —

     

     

     

     

    3,650

     

     

     

    (928

    )

     

     

    100

    %

     

    (100

    )%

    Impairment chargese

     

    —

     

     

     

     

    604

     

     

     

    2,170

     

     

     

    100

    %

     

    100

    %

    Acquisition and integration-related costsb

     

    2,041

     

     

     

     

    —

     

     

     

    4,216

     

     

     

    (100

    )%

     

    52

    %

    (Loss) income from operations

    $

    (977

    )

     

     

    $

    2,921

     

     

    $

    (3,433

    )

     

     

    (133

    )%

     

    72 

    %

    Cross Country Healthcare, Inc.

    Summary Condensed Consolidated Statements of Cash Flows

    (Unaudited, amounts in thousands)

     

     

     

     

     

     

     

    Three Months Ended

     

    March 31,

     

    March 31,

     

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2024

     

     

     

     

     

     

     

    Net cash provided by operating activities

    $

    5,681

     

     

    $

    6,011

     

     

    $

    24,234

     

    Net cash used in investing activities

     

    (1,886

    )

     

     

    (2,210

    )

     

     

    (2,531

    )

    Net cash used in financing activities

     

    (4,725

    )

     

     

    (15,653

    )

     

     

    (4,077

    )

    Effect of exchange rate changes on cash

     

    (6

    )

     

     

    —

     

     

     

    (14

    )

    Change in cash and cash equivalents

     

    (936

    )

     

     

    (11,852

    )

     

     

    17,612

     

    Cash and cash equivalents at beginning of period

     

    81,633

     

     

     

    17,094

     

     

     

    64,021

     

    Cash and cash equivalents at end of period

    $

    80,697

     

     

     

    5,242

     

     

    $

    81,633

     

     

     

     

     

     

     

    Cross Country Healthcare, Inc.

    Other Financial Data

    (Unaudited)

     

     

    Three Months Ended

     

    March 31,

     

    March 31,

     

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2024

     

     

     

     

     

     

     

    Revenue from services

    $

    293,408

     

     

    $

    379,174

     

     

    $

    309,940

     

    Less: Direct operating expenses

     

    234,750

     

     

     

    301,877

     

     

     

    247,948

     

    Gross profit

    $

    58,658

     

     

    $

    77,297

     

     

    $

    61,992

     

    Consolidated gross profit marginm

     

    20.0

    %

     

     

    20.4

    %

     

     

    20.0

    %

     

     

     

     

     

     

    Nurse and Allied Staffing statistical data:

     

     

     

     

     

    FTEsn

     

    7,411

     

     

     

    9,124

     

     

     

    7,621

     

    Average Nurse and Allied Staffing revenue per FTE per dayo

    $

    360

     

     

    $

    397

     

     

    $

    363

     

     

     

     

     

     

     

    Physician Staffing statistical data:

     

     

     

     

     

    Days filledp

     

    22,692

     

     

     

    23,785

     

     

     

    25,427

     

    Revenue per day filledq

    $

    2,253

     

     

    $

    1,976

     

     

    $

    2,085

     

    (a)

    Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on lease termination, gain or loss on sale of business, interest income, other expense (income), net, equity compensation, and system conversion costs. Adjusted EBITDA is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income (loss) attributable to common stockholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure as defined by the Company's credit facilities. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.

    (b)

    Acquisition and integration costs relate primarily to fees associated with the pending Aya Merger.

    (c)

    Restructuring costs were primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives.

    (d)

    Includes legal costs and other settlement charges as presented on the consolidated statements of operations and losses pertaining to matters outside the normal course of operations. The Company incurred a settlement expense of $1.2 million, and recorded a $1.8 million recovery related to a previous loss, in the fourth quarter of 2024. During the first quarter of 2024, the Company recorded legal and other losses of $3.7 million representing an offer to settle a lawsuit, as well as estimated costs related to an unrecoverable asset.

    (e)

    Impairment charges for the three months ended March 31, 2024 and December 31, 2024 were related to right-of-use assets and related property in connection with vacated leases in those periods. Impairment charges for the three months ended December 31, 2024 also included the write-off of goodwill and intangible assets associated with the impairment of a previous asset acquisition.

    (f)

    Interest income for the three months ended March 31, 2025 and December 31, 2024 related to higher average cash on hand with higher available interest rates.

    (g)

    System conversion costs include enterprise resource planning system costs related to the upgrading and integrating of our middle and back-office platforms, with certain development costs capitalized and amortized in accordance with the Company's policies.

    (h)

    Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders per diluted share before the diluted EPS impact of acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, system conversion costs, and nonrecurring income tax adjustments. Adjusted EPS is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes Adjusted EPS provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company than EPS. Quarterly non-GAAP adjustment may vary due to rounding.

    (i)

    Segment data is provided in accordance with the Segment Reporting Topic of the Financial Accounting Standards Board Accounting Standards Codification.

    (j)

    Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance.

    (k)

    Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and Company-wide projects (initiatives).

    (l)

    Legal and other losses (gains) include legal costs and other settlement charges as presented on the consolidated statements of operations and losses pertaining to matters outside the normal course of operations.

    (m)

    Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.

    (n)

    FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.

    (o)

    Average revenue per FTE per day is calculated by dividing Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.

    (p)

    Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours.

    (q)

    Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250506560790/en/

    Cross Country Healthcare, Inc.

    William J. Burns, Executive Vice President & Chief Financial Officer

    561-237-2555

    [email protected]

    Get the next $CCRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCRN

    DatePrice TargetRatingAnalyst
    12/10/2024Outperform → Mkt Perform
    Barrington Research
    12/6/2023Mkt Perform
    JMP Securities
    11/3/2023$32.00 → $21.00Buy → Hold
    Jefferies
    6/26/2023Outperform
    William Blair
    3/10/2023$30.00Buy
    Loop Capital
    10/5/2022$36.00Buy → Hold
    Truist
    2/24/2022$33.00 → $42.00Buy
    Benchmark
    1/27/2022$18.00 → $27.00Hold → Buy
    Jefferies
    More analyst ratings

    $CCRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cross Country Healthcare Announces First Quarter 2025 Financial Results

      Cross Country Healthcare, Inc. (the Company) (NASDAQ:CCRN) today announced financial results for its first quarter ended March 31, 2025. SELECTED FINANCIAL INFORMATION:       Variance Variance       Q1 2025 vs Q1 2025 vs Dollars are in thousands, except per share amounts Q1 2025 Q1 2024 Q4 2024 Revenue $ 293,408       (23 ) %   (5 ) % Gross profit margin*   20.0   %   (40 ) bps   —   bps Net loss attributable to common stockholders $ (490 )     (118 ) %   87   % Diluted EPS $ (0.02 )   $ (0.10 )

      5/7/25 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country Healthcare Stockholders Approve Aya Healthcare Transaction

      Cross Country Healthcare, Inc. ("Cross Country" or the "Company") (NASDAQ:CCRN) today announced that the Company has obtained all requisite stockholder approvals in connection with its proposed acquisition by Aya Healthcare. As previously disclosed, Cross Country and Aya Healthcare expect to complete the transaction in the second half of 2025, subject to the satisfaction or waiver of customary closing conditions specified in the Merger Agreement. Upon completion of the transaction, Cross Country will become a private company and its common stock will no longer trade on the NASDAQ. Cross Country will file the final, certified voting results on a Form 8-K with the U.S. Securities and Exch

      2/28/25 4:48:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Aya Healthcare to Acquire Cross Country Healthcare for Approximately $615 Million in Cash

      Cross Country stockholders to receive $18.61 per share Expands Aya's client service and delivery capabilities with Cross Country's nearly 40-year history of clinical excellence and quality patient care Provides clinicians with greater flexibility and convenience by tapping into the combined pool of nationwide opportunities, with competitive compensation and a world-class experience Creates immediate stockholder value for Cross Country, through a nearly 67 percent premium Aya Healthcare and Cross Country Healthcare today announced that they have entered into a definitive agreement whereby Aya will acquire Cross Country for $18.61 per share in cash in a transaction valued at appr

      12/4/24 7:45:00 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Financials

    Live finance-specific insights

    See more
    • Cross Country Healthcare Announces First Quarter 2025 Financial Results

      Cross Country Healthcare, Inc. (the Company) (NASDAQ:CCRN) today announced financial results for its first quarter ended March 31, 2025. SELECTED FINANCIAL INFORMATION:       Variance Variance       Q1 2025 vs Q1 2025 vs Dollars are in thousands, except per share amounts Q1 2025 Q1 2024 Q4 2024 Revenue $ 293,408       (23 ) %   (5 ) % Gross profit margin*   20.0   %   (40 ) bps   —   bps Net loss attributable to common stockholders $ (490 )     (118 ) %   87   % Diluted EPS $ (0.02 )   $ (0.10 )

      5/7/25 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country Healthcare to Hold Third Quarter 2024 Earnings Conference Call on Wednesday, November 6, 2024

      Cross Country Healthcare, Inc. (NASDAQ:CCRN) will hold its quarterly conference call to discuss its third quarter 2024 financial results on Wednesday, November 6, 2024 at 5:00 p.m. Eastern Time. Cross Country Healthcare, Inc. (the "Company") intends to distribute its earnings press release after market close on Wednesday, November 6, 2024. This call will be webcast live and can be accessed at the Company's website at ir.crosscountry.com or by dialing 888-566-1290 from anywhere in the U.S. or by dialing 773-799-3776 from non-U.S. locations – Passcode: Cross Country. A replay of the webcast will be available from November 6th through November 20th on the Company's website and a replay of the

      10/18/24 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country Healthcare Announces Second Quarter 2024 Financial Results

      Cross Country Healthcare, Inc. (the "Company") (NASDAQ:CCRN) today announced financial results for its second quarter ended June 30, 2024. SELECTED FINANCIAL INFORMATION:       Variance Variance       Q2 2024 vs Q2 2024 vs Dollars are in thousands, except per share amounts Q2 2024 Q2 2023 Q1 2024 Revenue $ 339,771       (37 ) %   (10 ) % Gross profit margin*   20.8   %   (200 ) bps   40   bps Net (loss) income attributable to common stockh

      7/31/24 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Cross Country Healthcare Inc.

      SCHEDULE 13G - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

      5/9/25 12:24:57 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • SEC Form 10-Q filed by Cross Country Healthcare Inc.

      10-Q - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)

      5/7/25 4:45:32 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)

      5/7/25 4:28:50 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cross Country downgraded by Barrington Research

      Barrington Research downgraded Cross Country from Outperform to Mkt Perform

      12/10/24 9:21:19 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • JMP Securities initiated coverage on Cross Country

      JMP Securities initiated coverage of Cross Country with a rating of Mkt Perform

      12/6/23 7:33:30 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Cross Country downgraded by Jefferies with a new price target

      Jefferies downgraded Cross Country from Buy to Hold and set a new price target of $21.00 from $32.00 previously

      11/3/23 7:41:51 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Group President, Delivery Krug Marc S. covered exercise/tax liability with 5,649 shares, decreasing direct ownership by 14% to 34,853 units (SEC Form 4)

      4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

      4/2/25 4:44:41 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Chief Financial Officer Burns William J. covered exercise/tax liability with 13,465 shares, decreasing direct ownership by 5% to 242,508 units (SEC Form 4)

      4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

      4/2/25 4:43:42 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • General Counsel and Secretary Ball Susan E covered exercise/tax liability with 9,386 shares, decreasing direct ownership by 5% to 176,032 units (SEC Form 4)

      4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

      4/2/25 4:43:08 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cash W Larry bought $61,320 worth of shares (6,000 units at $10.22), increasing direct ownership by 3% to 199,632 units (SEC Form 4)

      4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

      12/31/24 5:15:10 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Aya Healthcare to Acquire Cross Country Healthcare for Approximately $615 Million in Cash

      Cross Country stockholders to receive $18.61 per share Expands Aya's client service and delivery capabilities with Cross Country's nearly 40-year history of clinical excellence and quality patient care Provides clinicians with greater flexibility and convenience by tapping into the combined pool of nationwide opportunities, with competitive compensation and a world-class experience Creates immediate stockholder value for Cross Country, through a nearly 67 percent premium Aya Healthcare and Cross Country Healthcare today announced that they have entered into a definitive agreement whereby Aya will acquire Cross Country for $18.61 per share in cash in a transaction valued at appr

      12/4/24 7:45:00 AM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

      9/26/24 6:04:00 PM ET
      $CCRN
      $CHK
      $ENSG
      $SITC
      Professional Services
      Consumer Discretionary
      Oil & Gas Production
      Energy
    • Cross Country Healthcare Appoints Phillip Noe as Chief Information Officer

      Cross Country Healthcare, Inc., (NASDAQ:CCRN), a leading provider of advisory and workforce solutions including contingent staffing, permanent placement, and other consultative services for healthcare clients, has appointed Phillip Noe to the role of Chief Information Officer (CIO). Noe replaces Bill Halnon who is retiring, and will report directly to Kevin C. Clark, Co-founder and CEO. He commences May 10, 2021. "Phil's appointment reflects the ongoing evolution of our digital transformation at Cross Country," said Kevin C. Clark, Co-founder and Chief Executive Officer of Cross Country Healthcare. "His extensive experience in information technology spans every aspect of the software engin

      5/10/21 4:15:00 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary

    $CCRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cross Country Healthcare Inc.

      SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

      11/13/24 9:39:57 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Cross Country Healthcare Inc.

      SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

      11/13/24 4:36:10 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Cross Country Healthcare Inc. (Amendment)

      SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

      2/13/24 5:02:31 PM ET
      $CCRN
      Professional Services
      Consumer Discretionary